Post-streptococcal glomerulonephritis primary prevention: Difference between revisions
| Line 8: | Line 8: | ||
==Primary Prevention== | ==Primary Prevention== | ||
*Effective measures for the primary prevention of post-streptococcal glomerulonephritis include: | *Effective measures for the primary prevention of post-streptococcal glomerulonephritis include: | ||
** | **Spread of group A strep infection should be reduced by following methods:<ref name="urlGroup A Strep | Post-Streptococcal Glomerulonephritis | For Clinicians | GAS | CDC">{{cite web |url=https://www.cdc.gov/groupastrep/diseases-hcp/post-streptococcal.html |title=Group A Strep | Post-Streptococcal Glomerulonephritis | For Clinicians | GAS | CDC |format= |work= |accessdate=}}</ref> | ||
**Better housing | ***Improving hand hygiene | ||
**Prevent overcrowding | ***Better housing | ||
***Prevent overcrowding | |||
***Treatment of infected patient within 24 hours with antibiotics | |||
***Prevent close contact | |||
*A 26-valent vaccine is recommended for children to prevent post-streptococcal glomerulonephritis.<ref name="pmid16002631">{{cite journal |vauthors=Dale JB, Penfound T, Chiang EY, Long V, Shulman ST, Beall B |title=Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypes |journal=Clin. Diagn. Lab. Immunol. |volume=12 |issue=7 |pages=833–6 |date=July 2005 |pmid=16002631 |pmc=1182208 |doi=10.1128/CDLI.12.7.833-836.2005 |url=}}</ref> | *A 26-valent vaccine is recommended for children to prevent post-streptococcal glomerulonephritis.<ref name="pmid16002631">{{cite journal |vauthors=Dale JB, Penfound T, Chiang EY, Long V, Shulman ST, Beall B |title=Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypes |journal=Clin. Diagn. Lab. Immunol. |volume=12 |issue=7 |pages=833–6 |date=July 2005 |pmid=16002631 |pmc=1182208 |doi=10.1128/CDLI.12.7.833-836.2005 |url=}}</ref> | ||
Revision as of 14:50, 17 May 2018
|
Post-streptococcal glomerulonephritis Microchapters |
|
Differentiating Post-streptococcal glomerulonephritis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Post-streptococcal glomerulonephritis primary prevention On the Web |
|
American Roentgen Ray Society Images of Post-streptococcal glomerulonephritis primary prevention |
|
FDA on Post-streptococcal glomerulonephritis primary prevention |
|
CDC on Post-streptococcal glomerulonephritis primary prevention |
|
Post-streptococcal glomerulonephritis primary prevention in the news |
|
Blogs on Post-streptococcal glomerulonephritis primary prevention |
|
Directions to Hospitals Treating Post-streptococcal glomerulonephritis |
|
Risk calculators and risk factors for Post-streptococcal glomerulonephritis primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2]
Overview
Primary Prevention
- Effective measures for the primary prevention of post-streptococcal glomerulonephritis include:
- Spread of group A strep infection should be reduced by following methods:[1]
- Improving hand hygiene
- Better housing
- Prevent overcrowding
- Treatment of infected patient within 24 hours with antibiotics
- Prevent close contact
- Spread of group A strep infection should be reduced by following methods:[1]
- A 26-valent vaccine is recommended for children to prevent post-streptococcal glomerulonephritis.[2]
References
- ↑ "Group A Strep | Post-Streptococcal Glomerulonephritis | For Clinicians | GAS | CDC".
- ↑ Dale JB, Penfound T, Chiang EY, Long V, Shulman ST, Beall B (July 2005). "Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypes". Clin. Diagn. Lab. Immunol. 12 (7): 833–6. doi:10.1128/CDLI.12.7.833-836.2005. PMC 1182208. PMID 16002631.